Omadacycline as a promising tetracycline alternative for treating community-acquired bacterial pneumonia: Indian experience

IF 1.4 4区医学 Q4 IMMUNOLOGY

Indian Journal of Medical Microbiology Pub Date : 2025-03-30 DOI:10.1016/j.ijmmb.2025.100833

Yamuna Devi Bakthavatchalam , Yuvasri Manokaran , Ranjan Adhiya , Kamini Walia , Balaji Veeraraghavan

{"title":"Omadacycline as a promising tetracycline alternative for treating community-acquired bacterial pneumonia: Indian experience","authors":"Yamuna Devi Bakthavatchalam , Yuvasri Manokaran , Ranjan Adhiya , Kamini Walia , Balaji Veeraraghavan","doi":"10.1016/j.ijmmb.2025.100833","DOIUrl":null,"url":null,"abstract":"<div><div>Omadacycline, a novel tetracycline that has been approved for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSIs). In the present study, we evaluated the in-vitro activity of omadacycline against bacterial pathogens causing CABP. Non-duplicate isolates of methicillin susceptible Staphylococcus aureus (MSSA) (n = 105), methicillin resistant S. aureus (MRSA) (n = 102), Streptococcus pneumoniae (n = 100) and Moraxella catarrhalis (n = 102) were included. The minimum inhibitory concentration of omadacycline and other comparators were determined using the broth microdilution method. Overall, omadacycline potently inhibited MSSA (MIC90 0.25 mg/L), MRSA (MIC90 0.5 mg/L), S. pneumoniae (MIC90 0.06 mg/L) and M. catarrhalis (MIC90 0.12 mg/L) isolates. This finding reiterates that omadacycline could be a potential treatment alternative for treating severe CABP.</div></div>","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":"55 ","pages":"Article 100833"},"PeriodicalIF":1.4000,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Medical Microbiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0255085725000465","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Omadacycline, a novel tetracycline that has been approved for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSIs). In the present study, we evaluated the in-vitro activity of omadacycline against bacterial pathogens causing CABP. Non-duplicate isolates of methicillin susceptible Staphylococcus aureus (MSSA) (n = 105), methicillin resistant S. aureus (MRSA) (n = 102), Streptococcus pneumoniae (n = 100) and Moraxella catarrhalis (n = 102) were included. The minimum inhibitory concentration of omadacycline and other comparators were determined using the broth microdilution method. Overall, omadacycline potently inhibited MSSA (MIC₉₀ 0.25 mg/L), MRSA (MIC₉₀ 0.5 mg/L), S. pneumoniae (MIC₉₀ 0.06 mg/L) and M. catarrhalis (MIC₉₀ 0.12 mg/L) isolates. This finding reiterates that omadacycline could be a potential treatment alternative for treating severe CABP.

查看原文本刊更多论文

奥马达环素作为治疗社区获得性细菌性肺炎的有前途的四环素替代品：印度经验。

Omadacycline是一种新型四环素，已被批准用于治疗社区获得性细菌性肺炎（CABP）和急性细菌性皮肤和皮肤结构感染（ABSSIs）。在本研究中，我们评估了奥马达环素对引起CABP的细菌病原体的体外活性。包括非重复分离的甲氧西林敏感金黄色葡萄球菌（MSSA） 105株、耐甲氧西林金黄色葡萄球菌（MRSA） 102株、肺炎链球菌（100株）和卡他莫拉菌（102株）。采用微量肉汤稀释法测定了奥马达环素及其比较物的最低抑菌浓度。总体而言，奥马达环素有效抑制MSSA （MIC90 0.25 mg/L）、MRSA （MIC90 0.5 mg/L）、肺炎链球菌（MIC90 0.06 mg/L）和卡塔林分枝杆菌（MIC90 0.12 mg/L）分离株。这一发现重申，奥马达环素可能是治疗严重CABP的潜在替代治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian Journal of Medical Microbiology IMMUNOLOGY-

CiteScore

2.20

自引率

0.00%

发文量

154

审稿时长

73 days

期刊介绍： Manuscripts of high standard in the form of original research, multicentric studies, meta analysis, are accepted. Current reports can be submitted as brief communications. Case reports must include review of current literature, clinical details, outcome and follow up. Letters to the editor must be a comment on or pertain to a manuscript already published in the IJMM or in relation to preliminary communication of a larger study. Review articles, Special Articles or Guest Editorials are accepted on invitation.